Scarica l'app Stockscreener
1.27
4.51%
-0.06
Pre-mercato:
1.29
0.02
+1.57%
Precedente Chiudi:
$1.33
Aprire:
$1.26
Volume 24 ore:
3.95M
Relative Volume:
11.01
Capitalizzazione di mercato:
$2.59M
Reddito:
-
Utile/perdita netta:
$-11.27M
Rapporto P/E:
-0.0593
EPS:
-21.4132
Flusso di cassa netto:
$-9.40M
1 W Prestazione:
-11.81%
1M Prestazione:
+17.59%
6M Prestazione:
-26.39%
1 anno Prestazione:
-78.89%
Intervallo 1D:
$1.22
$1.38
Intervallo di 1 settimana:
$1.22
$1.4329
Portata 52W:
$1.00
$8.655
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Nome
Dermata Therapeutics Inc
Settore
Industria
Telefono
(858)-223-0882
Indirizzo
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Confronta DRMA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.27 | 2.59M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dermata Therapeutics Inc Borsa (DRMA) Ultime notizie
Dermata, Revance test new hyperhidrosis treatment By Investing.com - Investing.com South Africa
Dermata, Revance test new hyperhidrosis treatment - Investing.com India
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R) - Yahoo Finance
Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail
Dermata Therapeutics Inc (DRMA): Major Improvements, Worth A Look - Stocks Register
Dermata Therapeutics (NASDAQ:DRMA) Trading Up 1.2% – Still a Buy? - Defense World
Dermata Therapeutics, Inc. Receives Approval from FDA for the Proprietary Name Xyngarifor for Its Phase 3 Clinical Drug Candidate in Acne - Marketscreener.com
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) - AccessWire
Dermata's Acne Treatment 'Xyngari' Secures FDA Name Approval; Phase 3 Data Expected March 2025 - StockTitan
Dermata Therapeutics stock hits 52-week low at $1.05 By Investing.com - Investing.com UK
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - AccessWire
Dermata Secures Key Patent for Revolutionary Acne Treatment DMT310 Ahead of Phase 3 Results - StockTitan
DRMAWDermata Therapeutics, Inc. Warrant Latest Stock News & Market Updates - StockTitan
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - AccessWire
Dermata Therapeutics, Inc. Completes Enrollment in First Pivotal DMT310 Phase 3 Star-1 Clinical Trial for Acne - Marketscreener.com
ARMISTICE CAPITAL, LLC Increases Stake in Dermata Therapeutics I - GuruFocus.com
Dermata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Dermata Therapeutics stock hits 52-week low at $1.2 amid steep decline - Investing.com UK
Earnings Flash (DRMA) DERMATA THERAPEUTICS Reports Q3 Loss $-2.04 - Marketscreener.com
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - AccessWire
Dermata Hits 50% Enrollment in Phase 3 Acne Trial, Raises $7.8M in 2024 | DRMAW Stock News - StockTitan
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024 - The Manila Times
Dermata stock hits 52-week low at $1.22 amid market challenges - Investing.com Australia
Sponge Power: Dermata's Revolutionary Acne Treatment Trial Results Due In 2025 - RTTNews
Analyzing DRMA’s price-to-book ratio for the last quarter - US Post News
Dermata stock hits 52-week low at $1.28 amid market challenges - Investing.com UK
Acne Vulgaris Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2024-2034), States DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health - Barchart
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 - AccessWire
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.2% - Defense World
How does Dianthus Therapeutics Inc (DNTH) change from a tortoise to a hare? - SETE News
Ameritas Investment Partners Inc. Has $1.82 Million Stake in Dolby Laboratories, Inc. (NYSE:DLB) - Defense World
How to interpret Design Therapeutics Inc (DSGN)’s stock chart patterns - US Post News
The Dixie Group (NASDAQ:DXYN) Earns Hold Rating from Analysts at StockNews.com - Defense World
Darden Restaurants, Inc. (NYSE:DRI) Holdings Raised by XTX Topco Ltd - Defense World
Darden shares steady on neutral rating from Piper Sandler - Investing.com India
Darden stock 'ready to run' with delivery boost and sales initiativesBTIG By Investing.com - Investing.com South Africa
Ensysce Biosciences (NASDAQ:ENSC) Stock Quotes, Forecast and News Summary - Benzinga
Argent Trust Co Has $533,000 Stock Position in Darden Restaurants, Inc. (NYSE:DRI) - Defense World
Diamondback Energy 12.77M share Spot Secondary priced at $178.00 - TipRanks
Darden price target raised to $195 from $185 at Truist - TipRanks
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 7.5% - MarketBeat
Analytical Overview: Dermata Therapeutics Inc (DRMA)’s Ratios Tell a Financial Story - The Dwinnex
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - Kilgore News Herald
A Look at Dermata Therapeutics Inc (DRMA) Shares in the Recent Past Indicates Growth - SETE News
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - StockTitan
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - StockTitan
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September - Benzinga
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket - Benzinga
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
Acne Vulgaris Market Size is Set for Rapid Growth as Innovative - openPR
Dermata Therapeutics Inc Azioni (DRMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):